Dirk Reyn

Managing Partner

2016 - Current

Bioqube ventures has one mission: bringing early-stage healthcare companies to the next level. Entrepreneurial, result driven, shoulder to shoulder. Our team jointly represents over 40 years of leadership experience in identifying and funding promising scientific opportunities, is skilled in helping businesses grow and is deeply connected across corporate, government and academic research ecosystems. We cut cost, accelerate business and bring value by linking three key components: access to capital, specialized infrastructure and expertise. Our partnership with Johnson & Johnson Innovation – JLINX, is the embodiment of our mission: a multifaceted approach that enables early-stage healthcare companies to reach their full potential in a cost effective and time efficient way. Whether you are a scientist, entrepreneur or venture capitalist, bioqube ventures will face the challenge – working apart, and together with you.

Board Member

2025

flanders.bio and MEDVIA are joining forces in a brand new organization called FBM for the time being The members of flanders.bio and MEDVIA have voted to merge their activities in the first half of 2025. With a united voice, we will champion the entire biotech and healthtech ecosystem on the regional, federal and European stage. The merger allows flanders.bio and MEDVIA to align activities and deliver more powerful support for our collective members. We will achieve greater impact with more dynamic networking opportunities, better directed funding and increased efficiency, sharpening our focus in common areas and drafting strategic roadmaps for Flanders.

Board Member

2024

Enhanc3D Genomics was spun out from the laboratories of Dr. Stefan Schoenfelder and Professor Peter Fraser, who pioneered research into the dynamic spatial organisation of the genome at the Babraham Institute in Cambridge, UK. Our mission is to unlock the full potential of the human genome’s 3D organisation for target and biomarker discovery.

Health Advisor

2024

NPM Capital is an engaged and entrepreneurial private equity investment partner. They focus on companies that have a solid and competitive position in a growing market. Companies with the ambition to grow and a strong and dedicated management team. In addition to growth, their portfolio companies contribute to achieving a better and more sustainable world. This is why hey focus on investment themes including Feeding the World, Everything is Digital, Sustainable Future and Healthy Living & Learning.

Board Member

2021

According to Greek poet Hesiod, Aglaea (Egle) was the youngest of the Zeus Daughters Charites, symbolizing beauty, splendor, glory, and magnificence, all essential attributes to enlighten hope for patients suffering from severe diseases and to deploy unprecedent remarkable science to meet the unmet. Inspired by the myth of Aglaea, Egle Therapeutics has been built with the sole driver of assembling the most notable scientific expertise with genuine talents to bring well-being to the patient’s community. Established in early 2020, as a spin-out of Institut Curie, Egle Therapeutics is developing first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.

Chairman

2013

Progress pharma is a European development/biotech company that was created in June 2013 around a multi-functional and experienced team of former Movetis/Shire-Movetis senior managers. The company is located in Belgium, at the center of a very creative and dynamic biotech scene. Progress Pharma adopts a novel business model for asset-centric drug development. We turn the asset into a venture, whose mission is to advance the asset to the next phase - or further. We create a new company around this asset, along with the asset’s originator and specialized investment funds. Each party holds a participation in the venture, reflecting its contribution and its share in the development risk. Progress Pharma conducts the due diligence, develops the development and business plans, brings the co-investors to the table and runs the project in a cost-efficient manner. When the next development phase for the asset is attained, Progress Pharma paves the way for the next future of the venture – whether it is a new investment round, IPO, a trade sale or licensing … Our deepest expertise is in Gastroenterology, dermatology and immunology. We also have experience in diabetes, pain and women’s health, Progress Pharma has worked recently on a later stage asset in GI and is now working on an innovative phase I/II immunotherapy under its management.

President - Voorzitter van de Raad van Bestuur

2018 - 2025

The FlandersBio network brings together > 300 companies with innovative, R&D-driven activities in the life sciences – companies that are for example developing biopharmaceuticals, medical technologies or agricultural or industrial biotech products. Our network welcomes companies with production activities based in Flanders as well as academic research institutes and providers of capital, services and technologies to the life sciences community. FlandersBio's strategic goals are: Achieve sustainable economic growth Stimulate knowledge transfer Create a supportive regional environment Ensure a sufficient talent pool Increase public awareness

Chairman of Board

2018 - 2020

Across Health is a trusted advisor to senior leaders of innovative multinational healthcare organizations. With a focus on customer engagement in the digital age, we partner with our clients to design, develop, execute and measure evidence-based, omnichannel customer engagement strategies and company wide digital transformation and disruption programmes – for the short, medium and long term.

Co-founder and Board member

2018 - 2020

Spectricity is a spin-off of IMEC, a leading R&D center in nanoelectronics and digital technologies in Belgium. Spectricity develops low-cost, miniaturized, integrated spectral sensing solutions in the visible and near-infrared spectral range. Typical application areas are agriculture, food analysis, health, and biomedical applications for industrial and consumer markets.

Past President Rotary Turnhout

2017 - 2018